Hiromichi Katakura
Kyoto University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiromichi Katakura.
Journal of Clinical Oncology | 2002
Tsuyoshi Shoji; Fumihiro Tanaka; Tetsuya Takata; Kazuhiro Yanagihara; Yosuke Otake; Nobuharu Hanaoka; Ryo Miyahara; Tatsuo Nakagawa; Yozo Kawano; Shinya Ishikawa; Hiromichi Katakura; Hiromi Wada
PURPOSE The clinical significance of p21 expression remains unclear, whereas many experimental studies have demonstrated that p21, the product of the WAF1/CIP1/SDI1 gene, plays an important role in regulation of the cell cycle as an inhibitor of cyclin-dependent kinases. The purpose of this study was to clarify the clinical significance in resected non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS A total of 233 consecutive patients with completely resected pathologic stage I to IIIA NSCLC were retrospectively reviewed. Expression of p21 and the status of p53 were examined immunohistochemically. Proliferative activity was also evaluated immunohistochemically. The incidence of apoptotic cell death was evaluated by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling staining. RESULTS Expression of p21 was positive in 120 patients (51.5%). The 5-year survival rate of p21-positive patients was 73.8%, significantly higher than that of p21-negative patients (60.7%; P =.006). Aberrant expression of p53 was positive in 98 patients (42.1%). When combined with p53 status, the prognostic value of p21 status was enhanced: the 5-year survival rate of p21-positive and p53-negative patients was 80.7%, markedly higher than that of p21-negative and p53-positive patients (50.0% for both; P =.001). Multivariate analysis confirmed that positive expression of p21 was a significant factor for predicting a favorable prognosis. There was no significant correlation between p21 expression and p53 status, proliferative activity, or incidence of apoptosis. CONCLUSION p21 expression was shown to be an independent prognostic factor in NSCLC.
Annals of Surgical Oncology | 2004
Fumihiro Tanaka; Kazuhiro Yanagihara; Yosuke Otake; Yozo Kawano; Ryo Miyahara; Kazumasa Takenaka; Hiromichi Katakura; Shinya Ishikawa; Harumi Ito; Hiromi Wada
BackgroundPostoperative prognosis for patients with pathologic (p-) stage IIIA-N2 non-small-cell lung cancer (NSCLC) is poor, and significant factors that influence the prognosis remain unclear.MethodsA total of 99 patients who underwent complete resection for p-stage IIIA-N2 NSCLC without any preoperative therapy were retrospectively reviewed. Biological features such as tumor angiogenesis (intratumoral microvessel density [IMVD]), proliferative activity (proliferative index [PI]), and p53 status were also evaluated immunohistochemically.ResultsUnivariate analysis revealed that the number of involved N2 stations was a significant prognostic factor; 5-year survival rates for a tumor with metastases in single N2 stations, tumor with metastases in two N2 stations, and tumor with metastases in 3 or more N2 stations were 41.6%, 35.3%, and 0.0%, respectively (P = .041) In addition, the 5-year survival rate for cN0-1 disease was significantly higher than that for cN2 disease (41.9% and 25.5%, respectively; P = .048) Tumor angiogenesis and proliferative activity were the most significant prognostic factors; 5-year survival rates for lower-IMDV tumor and higher-IMVD tumor were 53.6% and 15.9%, respectively (P = .002), and those for lower-PI tumor and higher-PI tumor were 47.0% and 20.4%, respectively (P = .019) There was no difference in the postoperative survival between tumor showing aberrant p53 expression and tumor showing no aberrant p53 expression. These results were confirmed by a multivariate analysis.ConclusionsP-stage IIIA-N2 NSCLC cases represented a mixture of heterogeneous prognostic subgroups, and the number of involved N2 stations, cN status, PI, and IMVD were significant predictors of the survival.
Journal of Gene Medicine | 2004
Hiromichi Katakura; Atsushi Harada; Kazunori Kataoka; Miki Furusho; Fumihiro Tanaka; Hiromi Wada; Kazuhiro Ikenaka
Although some cationic reagents, such as polybrene, improve gene transduction in vitro, their use in vivo is prohibited due to their toxicity to the exposed cells. This paper demonstrates that a new cationic reagent, poly(ethylene glycol)‐poly(L‐lysine) block copolymer (PEG‐PLL), improves gene transduction with retroviral vectors without increasing cell toxicity.
The Annals of Thoracic Surgery | 2002
Hiromichi Katakura; Fumihiro Tanaka; Hiroki Oyanagi; Ryo Miyahara; Kazuhiro Yanagihara; Yosuke Otake; Hiromi Wada
BACKGROUND Clinical significance of the status of nm23 gene, originally identified as an antimetastatic gene, in non-small cell lung cancer remains unestablished, whereas many clinical studies have demonstrated that reduced nm23 expression is correlated with tumor progression and poor prognosis in a variety of malignant tumors such as breast carcinoma. METHODS nm23 expression was examined immunohistochemically in a total of 117 patients with completely resected pathologic stage I non-small cell lung cancer. RESULTS nm23 expression was positive in 73 (62.4%) patients, and there was no correlation between nm23 expression and age, sex, performance status, pathologic T factor, histologic type, or degree of cancer cell differentiation. The 5-year survival rates of nm23-positive and nm23-negative patients were 79.7% and 57.8%, respectively, demonstrating a significantly poorer prognosis in nm23-negative patients (p = 0.013), which was confirmed by a multivariate analysis. nm23 was not correlated with the incidence of apoptosis, proliferative activity, or p53 status. CONCLUSIONS nm23 expression was a significant factor for predicting a favorable prognosis, suggesting antimetastatic potential of the nm23 gene in non-small cell lung cancer.
The Annals of Thoracic Surgery | 2013
Yojiro Yutaka; Akari Fukao; Tomoyuki Shirase; Kenichi Takahashi; Hiromichi Katakura; Naoki Sakai; Akira Yamanaka
Hepatic hydrothorax is defined as the presence of a pleural effusion in a patient with liver cirrhosis in the absence of cardiopulmonary disease, and it is a devastating complication impairing quality of life in the end stage of liver disease. The management of the effusion is challenging, and chest tube drainage can sometimes cause more serious complications by removing massive amounts of protein-rich fluid. Though the most plausible mechanism is the influx of ascites to the pleural cavity through a small diaphragmatic defect, the defect often cannot be found. Hepatic hydrothorax could be controlled by repairing an invisible defect of the diaphragm. With pneumoperitoneum after intraperitoneal administration of indocyanine green, the defect, clearly dyed green, appeared on the diaphragm. This novel combination technique could be useful for ensuring the surgical repair of an invisible diaphragmatic defect.
Interactive Cardiovascular and Thoracic Surgery | 2018
Masatsugu Hamaji; Atsushi Kawaguchi; Mitsugu Omasa; Tatsuo Nakagawa; Ryota Sumitomo; Cheng-long Huang; Takuji Fujinaga; Masaki Ikeda; Tsuyoshi Shoji; Hiromichi Katakura; Hideki Motoyama; Toshi Menju; Akihiro Aoyama; Toshihiko Sato; Toyofumi F. Chen-Yoshikawa; Makoto Sonobe; Hiroshi Date
OBJECTIVES Previous studies have suggested that a second malignancy often develops after resection of thymoma; however, it remains unknown whether this is applicable to thymic carcinoma. METHODS A retrospective chart review was performed based on our multi-institutional database of resected thymic epithelial tumours between 1991 and 2016. A second malignancy was defined as newly diagnosed after thymic tumour resection. The cumulative incidence of and related death from a second malignancy after thymic and neuroendocrine carcinoma resections were estimated using a competing risk model and were compared to those of patients undergoing a thymoma resection. RESULTS Two hundred and thirty-eight patients were identified (thymic carcinoma 59; thymoma 179). A second malignancy developed in 1 patient (1.7%) with thymic carcinoma and in 17 patients (9.5%) with thymoma. Deaths from second malignancies were noted in 7 patients with thymoma. There was a tendency towards a lower cumulative incidence of and a lower cumulative death from a second malignancy after thymic carcinoma resection (P = 0.139 and P = 0.20, respectively) than after thymoma resection. The cumulative incidence of a second malignancy in patients with thymic carcinoma was 2.8% at 5 years and at 10 years (8.0% at 5 years and 11.8% at 10 years in patients with thymoma). CONCLUSIONS After resection of thymic and thymic neuroendocrine carcinoma, the probability of developing a second malignancy, as well as mortality from a second malignancy, is very low. A prospective study with a larger sample size is required to validate our results.
Surgical Case Reports | 2017
Hiromichi Katakura; Yojiro Yutaka; Kenichi Takahashi; Tsuyoshi Shoji; Akira Yamanaka; Mitsuru Kitano
Median sternotomy is frequently selected for the resection of pulmonary artery tumor, and pneumonectomy is performed for complete resection. However, it is difficult to see the inferior pulmonary vein and transect it safely via median sternotomy, so additional thoracotomy is often required and this is highly invasive. In the present case, we employed thoracoscopy (which we routinely use for VATS lobectomy) to transect the inferior pulmonary vein via median sternotomy without additional intercostal thoracotomy. This method has advantages for patients undergoing pneumonectomy via median sternotomy.
Cancer Research | 2001
Manabu Sasaki; Kensuke Nakahira; Yozo Kawano; Hiromichi Katakura; Toshiki Yoshimine; Keiji Shimizu; Seung U. Kim; Kazuhiro Ikenaka
Annals of Surgical Oncology | 2008
Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal of Surgical Oncology | 2007
Makoto Sonobe; Masatsugu Nakagawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Kazuhiro Yanagihara; Yosuke Otake; Hiromi Wada; Fumihiro Tanaka
Collaboration
Dive into the Hiromichi Katakura's collaboration.
University of Occupational and Environmental Health Japan
View shared research outputs